1. Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer

   • Milin R. Acharya
   • Judith E. Karp
   • Alex Sparreboom

   Preclinical Studies 31 March 2006 Pages: 367 - 375

2. The effect of single agent oral fusaric acid (FA) on the growth of subcuta neously xenografted SCC-1 cells in a nude mouse model

   • James M. Ruda
   • Kirt S. Beus
   • Brendan C. Stack Jr.

   Preclinical Studies 24 February 2006 Pages: 377 - 381

3. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs

   • Ada Rephaeli
   • Michal Entin-Meer
   • Abraham Nudelman

   Preclinical Studies 24 February 2006 Pages: 383 - 392

4. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes

   • William C. Zamboni
   • Ramesh K. Ramanathan
   • Sharon Marsh

   Preclinical Studies 09 March 2006 Pages: 393 - 401

5. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies

   • G. Schwartsmann
   • L. P. DiLeone
   • G. De Nucci

   Phase I Studies 24 February 2006 Pages: 403 - 412

6. Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx^®) in combination with topotecan in patients with advanced malignancies

   • Hervé Ghesquières
   • Sandrine Faivre
   • Eric Raymond

   Phase I Studies 22 April 2006 Pages: 413 - 421

7. Phase 1 trial of Anvirzel™ in patients with refractory solid tumors

   • Tarek Mekhail
   • Hanspreet Kaur
   • Ronald M. Bukowski

   Phase I Studies 05 April 2006 Pages: 423 - 427

8. Phase II study of vinflunine in patients with metastatic renal cell carcinoma

   • D. Goldstein
   • S. P. Ackland
   • M. Byrne

   Phase II Studies 08 March 2006 Pages: 429 - 434

9. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial

   • M. Knowling
   • M. Blackstein
   • E. Eisenhauer

   Phase II Studies 09 March 2006 Pages: 435 - 439

10. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane

    • J. A. Ajani
    • H. Safran
    • B. Mullaney

    Phase II Studies 31 March 2006 Pages: 441 - 446

11. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282

    • Minaxi Jhawer
    • Sridhar Mani
    • Daniel Haller

    Phase II Studies 22 April 2006 Pages: 447 - 454

12. Abraxane^® induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency

    • J. Lee Villano
    • Divyesh Mehta
    • Latha Radhakrishnan

    Case Report 24 February 2006 Pages: 455 - 456